Skip to Content



In line with our commitment to transparency, Almirall presents this section dedicated to our shareholders and investors. It includes all information required by the applicable law for corporate matters in addition to other information considered relevant for investors.



Almirall 9M Results 2016: Strong Derma performance in EU and solid progress in US

Barcelona, 7 th November, 2016 .- Almirall, the global pharmaceutical company based in Barcelona, has announced its 9M ...


Almirall announces a restructuring plan in Spain

Almirall SA has announced today a restructuring plan in Spain, which will affect a maximum of 121 people, with the ai ...

Discover the upcoming events.

Upcoming Conference calls